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Aspergillus fumigatus (A. fumigatus) is a ubiquitous fungus of clinical importance
associated with development of various pulmonary diseases and allergic hypersensitivity
reactions. It is protected against environmental stress by a cell wall that contains
polysaccharides such as chitin. We previously demonstrated that fibrinogen C
domain-containing protein 1 (FIBCD1) is a membrane-bound protein that binds
chitin through a conserved S1 binding site and is expressed in intestinal epithelium
and salivary glands. Here, we further localized FIBCD1 protein expression at the
surface of bronchial and alveolar human lung epithelium, observed recognition of A.
fumigatus cell wall with S1 site-independent recognition. We observed FIBCD1-mediated
suppression of IL-8 secretion, mucin production, and transcription of genes associated
with airway inflammation and homeostasis in FIBCD1-transfected lung epithelial cells.
These modulations were generally enforced by stimulation with A. fumigatus cell wall
polysaccharides. In parallel, we demonstrated a FIBCD1-mediated modulation of IL-8
secretion induced by TLR2,−4, and −5. Collectively, our findings support FIBCD1
as a human lung epithelial pattern recognition receptor that recognizes the complex
A. fumigatus cell wall polysaccharides and modulates the lung epithelial inflammatory
response by suppressing inflammatory mediators and mucins.
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INTRODUCTION
Aspergillus fumigatus (A. fumigatus) is a ubiquitous, filamentous fungus with the ability to cause
invasive and allergic pulmonary diseases that is partly attributed to its ability to circumvent host
immune defenses at airway mucosal sites (1–4). Humans inhale several hundred A. fumigatus
conidia every day and their small size make them easily aerosolized and capable of reaching the
lung alveoli. In healthy, immune-competent hosts, inhaled A. fumigatus conidia are cleared by
innate defense mechanisms including mucociliary transport mechanisms and phagocytic activity
of leukocytes, primarily residential macrophages and neutrophils recruited by epithelial secretion
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of chemotactic factors such as IL-8. Additionally, epithelial
secretion of opsonizing mediators such as ficolins and
complement components support the activity of these
mechanisms (5, 6).
A cell wall, mainly composed of polysaccharides and secretory
antigens, protects A. fumigatus conidia and hyphae against
environmental stress (7). The structural skeleton of the cell
wall is composed of chitin and galactomannan covalently bound
to β-1,3-glucan (8), which are polysaccharide structures absent
in mammals. Therefore, they serve as pathogen-associated
molecular patterns (PAMPs) recognized by pattern recognition
receptors (PRRs) on mammalian cells (9). The A. fumigatus
cell wall is continuously remodeled during morphogenesis
from inhaled, resting conidia to fully-grown hyphae (10). In
resting conidia, the cell wall is protected by an additional
layer of hydrophobic proteins and pigments, not produced in
germ tubes and hyphae. This layer shields A. fumigatus cell
wall PAMPs, which makes the resting conidia immunologically
inert (9). During the first stages of germination, cell wall
polysaccharides are hydrolyzed and de novo synthesis of cell
wall components, e.g. chitin and β-1,3-glucan, is initiated (10).
This causes the conidia to swell, disintegrating the outer layer
and exposing cell wall PAMPs to host PRRs (9). Various PRRs
are involved in the initiation, control, and resolution of the
anti-A. fumigatus inflammatory response (11), including Toll-
Like Receptors (TLRs) (5, 6) and the β-1,3-glucan receptor
Dectin-1 (12). Several studies report a TLR-regulated anti-A.
fumigatus response dependent on the fungus’ morphotype (5,
6, 13). However, the underlying mechanisms remain unknown
and may involve interplay between other PRRs that recognize A.
fumigatus-associated PAMPs.
We have previously identified fibrinogen C domain-
containing protein 1 (FIBCD1) as the first membrane-bound
protein of the fibrinogen-related domain (FReD) superfamily
(14). FIBCD1 is expressed as a tetramer on the apical surface
of small and large intestinal epithelium and is composed of a
cytoplasmic tail with three potential phosphorylation sites, a
transmembrane region, and an ectodomain containing a coiled-
coil region, a polycationic region, and a FReD (14). FIBCD1
exhibits calcium-dependent binding of acetylated structures
including crab shell chitin through a conserved S1 binding site in
FReD and facilitates endocytosis of bound ligands (14, 15). The
crystal structure of FIBCD1-FReD (16) is homologous to FReD
superfamily members involved in immune regulation, including
ficolin-1 and −2 (17, 18). Both ficolin-1 and −2 recognize
A. fumigatus-associated PAMPs (19, 20) and binds directly or
indirectly to resting A. fumigatus conidia (21).
The aim of this study is to investigate the potential role
of FIBCD1 in the immune response against A. fumigatus. We
Abbreviations: acBSA, acetylated BSA; A. fumigatus, Aspergillus fumigatus; AIF,
alkali-insoluble fraction; CNRQ, calibrated normalized relative quantity; DPBS,
Dulbecco’s PBS; FIBCD1, fibrinogen C domain-containing protein 1; FReD,
fibrinogen-related domain; IAA, iodoacetamide; IHC, Immunohistochemical;
MBL, mannan-binding lectin; MOPS, 3-(N-morpholino)propanesulfonic acid;
MUC, mucin; PAMPs, pathogen-associated molecular patterns; PRR, pattern
recognition receptor; qPCR, quantitative PCR; RT, room temperature; SD,
sabouraud dextrose; WGA, wheat germ agglutinin.
hypothesize that FIBCD1 is expressed in human lung epithelium
and interacts with A. fumigatus by binding fungal cell wall chitin
in the S1 binding site of FIBCD1-FReD. We hypothesize that
interaction between FIBCD1 and ligand(s) modulates TLR- and
lung epithelial cell-mediated inflammatory response to fungal cell
wall components.
METHODS AND MATERIALS
Buffers and Reagents
PBS: 140mM NaCl, 3mM KCl, 8mM Na2HPO4, 1.5mM
KH2PO4. TBS: 10mM Tris-base, 140mM NaCl. SDS-
PAGE sample buffer: 374mM Tris-base, 40% (v/v) glycerol,
3mM bromophenol blue, 8% (w/v) SDS. Acetylated BSA
(acBSA), BSA, citric acid, EDTA, glycine, glycerol, silver
nitrate (AgNO3), SDS, sodium azide (NaN3), Tris-base,
Triton X-100, H2SO4, iodoacetamide (IAA), DTT, CaCl2,
sodium acetate, NaHCO3, sterile PBS, curdlan (β-1,3-glucan,
from Alcaligenes faecalis), RNase ZAP R©, M-MLV reverse
transcriptase, and oligo-dT primers were ordered from Sigma-
Aldrich Co., St Louis, MO, United States. Alexa Fluor 488,
Alexa Fluor 633-labeled wheat germ agglutinin (WGA), Gateway
Technology R© pDONRTM-221 vector, 3-(N-morpholino)-
propanesulfonic acid (MOPS) running buffer, RPMI media,
FBS, L-glutamine, penicillin/streptomycin, hygromycin B,
trypsin/EDTA, Dulbecco’s PBS (DPBS), DMSO, TRIzol reagent,
and RNaseOUTTM recombinant ribonuclease inhibitor were
ordered from InvitrogenTM, Thermo Fisher Scientific Inc.,
Waltham, MA, United states. Sabouraud dextrose (SD) agar,
SD broth media, and 40-µm cell strainer were ordered from
BD Biosciences, Franklin Lakes, NJ, United States. Acetic
acid, bromophenol blue, formaldehyde, KCl, KH2PO4, NaCl,
Na2HPO4, Na2CO3, NaOH, Tween 20, and mira cloth were
ordered from Merck KGaA, Darmstadt, Germany. Four to
twelve percent of polyacrylamide gradient gels, Precision
Plus ProteinTM KaleidoscopeTM Standards, and non-fat dry
milk were ordered from Bio-Rad Laboratories, Inc., Hercules,
CA, United States. Chitin beads were ordered from New
England Biolabs Inc., Ipswich, Massachusetts, USA, and
Dectin-1Fc was kindly provided by Prof Gordon Brown,
Aberdeen University. HRP-conjugated rabbit anti-mouse
Ig (#P0260), FITC-conjugated goat anti-mouse antibody
(#F0479), and HRP-conjugated goat anti-rabbit Ig (#P0448)
were ordered from Dako, Glostrup, Denmark. D-galacto-D-
mannan (from Ceratonia Siliqua) and mouse monoclonal
anti-GAPDH antibody (#sc32233) were ordered from Santa
Cruz Biotechnologies, Inc., Dallas, TX, United States.
The anti-mucin (MUC) antibodies rabbit monoclonal anti-
MUC-1 antibody (#ab45167), rabbit polyclonal anti-MUC-13
antibody (#ab65109), and mouse monoclonal anti-MUC-5AC
antibody (#ab11335) were ordered from Abcam plc, Cambridge,
United Kingdom. Protein G column, polyvinylidene difluoride
membrane, filter paper, and ECL kit were ordered from
GE Healthcare, Little Chalfont, United Kingdom. Ambion R©
nuclease-free water, custom TaqMan R© array 96-well plates, and
2 X TaqMan R© fast advanced master mix were ordered from
Thermo Fisher Scientific Inc., Waltham, MA, United states.
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The human TLR agonist kit was ordered from InvivoGen, San
Diego, CA, United States. Alphazyme was ordered from PAA
Laboratories GmbH, Pasching, Austria. O-phenylendiamid was
ordered from Kem-En-Tec Diagnostics A/S, Taastrup, Denmark.
Human CXCL8/IL-8 DuoSet kit was ordered from R&D Systems,
Inc., Minneapolis, MN, United states. Limulus amebocyte lysate
assay (QCL-1000TM) was ordered from Lonza Group Ltd., Basel,
Switzerland. Protease inhibitor cocktail tablets were ordered
from Roche Diagnostics, Basel, Switzerland. Commercial cDNA
library and FIBCD1 PerfectProbeTM assay were ordered from
Primerdesign Ltd., United Kingdom. JetPEI transfection reagents
were ordered from Polyplus transfection SA, Illkirch, France.
Monoclonal anti-ovalbumin antibody was ordered from SSI,
Copenhagen, Denmark. The murine Sp2/mIl-6 (CRL-2016)
myeloma cells and human lung carcinoma type II epithelial-like
A549 cell line were purchased from the American type culture
collection (Rockville, MD, USA).
Real Time Analysis of FIBCD1 Expression
in Human Tissues
The relative tissue distribution of human FIBCD1 mRNA
was quantitated using a commercial cDNA library and
a custom made FIBCD1 PerfectProbeTM assay with the
primer sequences 5′-CACCGTGGCTGACTATTCC-3′ and
5′-TTCTCTGAATGGTCGCTGTC-3′. Analysis was performed
in triplicates using the cycling conditions: 95◦C for 10min,
followed by 50 cycles of 95◦C for 15 s, 60◦C for 30 s and 72◦C for
15 s. The study was performed on a 7500 Real-time PCR system
(Applied Biosystems R©, Thermo Fisher Scientific Inc., Waltham,
MA, USA) using 18S RNA for normalization.
Expression and Purification of
Recombinant FIBCD1-FReD (rfibcd1-FReD)
rFIBCD1-FReD was expressed in insect cells and purified on
N-acetylated immobilized resin as described previously (15).
Production of Monoclonal Anti-FIBCD1
Antibodies
Mouse monoclonal anti-FIBCD1 antibodies HG-HYB-12-
2,−12-5, and−12-6 were produced as previously described (14).
Mouse monoclonal anti-FIBCD1-FReD antibody HYB-11-14-25
was produced by immunization of Fibcd1−/− C57BL6/n mice.
The mice were immunized twice with 20 µg of rFIBCD1-
FReD using GERBU as adjuvant with more than 2 weeks
between each immunization. The mice were boosted once by an
intra-peritoneal injection with 20 µg rFIBCD1-FReD without
adjuvant 3 days before isolation of B cells. Hybridoma cells
were produced by fusion between isolated B cells and myeloma
cells and adapted for serum-free media. Secreted antibodies
were purified using a protein G column on a fast protein
liquid chromatography apparatus (ÄKTA, GE Healthcare,
Little Chalfont, United Kingdom). These experiments were
performed under license from the National Animal Experiments
Inspectorate (reference no. 2012–15–2934–00076).
Immunohistochemical Analysis of FIBCD1
in Human Lung Tissue
Human tissues were obtained from the tissue bank at the
Department of Pathology, Odense University Hospital (Odense,
Denmark). The tissues were fixed in 4% formalin in PBS for 24 h
and then conventionally dehydrated and embedded in paraffin.
A biotin-streptavidin immunoperoxidase technique was used on
paraffin sections. Paraffin sections were pre-treated in TEG buffer
(10 mmol/L Tris, 0.5 mmol/L EGTA, pH 9) in a microwave
oven for three 5min periods at 650W. The sections were left in
TEG buffer for 15min, washed in TBS, pre-incubated with 2%
(w/v) BSA in TBS for 10min, and incubated for 30min with the
mouse anti-human FIBCD1 (HG-HYB-12-2, 0.5 mg/mL) in TBS
containing 15% (w/v) BSA and otherwise processed as described
byMadsen et al. (22). The specificity of the immuno-staining was
verified by replacing the primary antibody with a non-specific
antibody. The local ethical committee in Odense approved the
use of human tissue samples (ref. no: VF20050070).
Fungal Strain and Growth Conditions
A. fumigatus conidia (101355, Centraalbureau von
Schimmelcultures, Utrecht, Netherlands) were cultivated
on SD agar plates at 37◦C for 5 days and harvested using
PBS/0.5% Tween, washed, and used immediately or stored at
4◦C. A. fumigatus germination was obtained by inoculating
SD broth media with freshly-harvested conidia (less than a
week after harvest) and incubating at 37◦C. For production of
a 1-week-culture, 104 freshly-harvested conidia were added per
mL media in an Erlenmeyer flask containing 1:4 volume media
and incubating at 37◦C, 100–140 rpm for 7 days.
Alexa Fluor 488-Labeling of rFIBCD1-FReD
Purified protein (2 mg/mL) was labeled with Alexa Fluor 488 in
a 1:9 molar ratio at RT for 1–2 h according to manufacturer’s
recommendations followed by extensive dialysis against PBS to
remove excess dye. Activity of labeled rFIBCD1-FReD was tested
by binding to acBSA. Labeled protein was stored at 4◦C until
used.
Staining of A. fumigatus
Staining of A. fumigatus was performed by a modification of
previously describedmethods (23) and imaged using anOlympus
IX71 fluorescence microscope equipped with four laser optics
and F-view fluorescence CCD camera (Olympus Corporation,
Tokyo, Japan). All images were acquired and processed using
CellF soft imaging software (Olympus Corporation, Tokyo,
Japan).
Preparation of A. fumigatus
Alkali-Insoluble Fraction (AIF)
A. fumigatus cell wall component suspension (i.e., alkali-
insoluble fraction) was prepared as previously described with
minor modifications (8). Briefly, mycelium was harvested from
one-week-culture by filtration through mira cloth, washed with
distilled PBS, and subjected to three hot alkali treatments
(distilled 1M NaOH, 65◦C heat bath, 30min), each followed by
five washes with distilled water and one with distilled TBS at
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10,000 × g for 10min. The product was grinded with mortar
and pestle, washed with sterile PBS, forced through a 40µm
cell strainer, pH adjusted to ∼7, added 0.05% NaN3, and the
final product stored at 4◦C. AIF was tested for endotoxin
contamination using a limulus amebocyte lysate assay revealing
an endotoxin level below 0.25 endotoxin units per mL. The
absence of protein was confirmed by boiling AIF 1:2 in SDS-
PAGE sample buffer on a 99◦C heating block for 1min and
separating eluted protein on a 4–12% polyacrylamide gradient
gel using MOPS running buffer and subsequently silver staining
the gel as described in the following section. The concentration
was determined by vacuum drying using a MAXI-dry vacuum
centrifuge (Heto-Holten A/S, Alleroed, Denmark) at 55◦C, 1,300
rpm.
Pull Down Assay
For protein staining, 2mg of AIF was washed three times with
TBS/0.05% Tween/5mM CaCl2 and incubated at 4◦C overnight
with 20µg/mL Dectin-1Fc, recombinant mannan-binding lectin
(rMBL), WGA, and rFIBCD1-FReD in a total volume of 1mL.
Pull down was performed by centrifugation at 4◦C, 10,000 × g
for 5min. The insoluble pellets were washed three times with
TBS/0.05% Tween/5mM CaCl2 and bound protein was eluted
by boiling the pellets in SDS-PAGE sample buffer for 1min.
For Western blotting, 2mg AIF and β-1,3-glucan and 200 µL
chitin beads were washed three times with TBS/0.05% Tween
and incubated at 4◦C overnight with 5µg/mL rFIBCD1-FReD
in a total volume of 1mL TBS/0.05% Tween supplemented
with 5mM CaCl2, 10mM EDTA, or 100mM sodium acetate.
Pull down was performed by centrifugation at 5,000 rpm
(Minispin, Eppendorf AG, Hamburg, Germany) for 5min. The
insoluble pellets were washed three times with TBS/0.05% Tween
supplemented with 5mM CaCl2, 10mM EDTA, or 100mM
sodium acetate and bound protein was eluted by boiling the
pellets in SDS-PAGE sample buffer on a 99◦C heating block for
1min. Pull down of mutant FIBCD1-FReD (A432V) by AIF and
chitin beads was performed as previously described (15). Eluted
protein was separated by SDS-PAGE on a 4–12% polyacrylamide
gradient gel using MOPS running buffer and analyzed by silver
staining orWestern blotting as described in the following section.
Silver Staining
Silver staining of proteins separated by SDS-PAGE was
performed as previously described (24) with some modifications
(Supplementary Datasheet 2).
Generation of A549 Cells Expressing Full
Length of FIBCD1
To generate A549 cells stably expressing full length FIBCD1, the
cells were transfected with the expression vector pDEST-FIBCD1
using JetPEI transfection reagents according to manufacturer’s
instructions. The pDEST-FIBCD1 vector was constructed using
Gateway Technology R© and keeping to the recommendations
of the manufacturer using cDNA containing the open reading
frame of FIBCD1, donor vector pDONRTM-221, and destination
vector pDEST. A corresponding sham-transfected isogenic
control cell type was constructed using a pDEST-sham vector.
Cells were selected for stable integration of vectors using
500µg/mL of hygromycin B. Successful expression of FIBCD1
protein was confirmed by Western blotting of cell lysates
(Supplementary Datasheet 2) and surface expression of FIBCD1
was confirmed by flow cytometry. Unless otherwise stated,
A549 cells were maintained in serial passages at 37◦C, 5% CO2
humidity in RPMI media supplemented with 10% FBS, 2mM L-
glutamine, 250µg/mL hygromycin B, 50 U/mL penicillin, and
50µg/mL streptomycin. When confluent, cells were subcultured
by washing twice in sterile DPBS, detaching with 1mL 0.5%
trypsin/EDTA/sterile DPBS, and diluted using fresh complete
media.
Flow Cytometry
A549 cells were harvested by incubation with alphazyme and
centrifugation at 350 × g for 5min. Cells were suspended
in media, counted using a haemocytometer, portioned out in
minisorp tubes (106 cells/tube), pelleted by centrifugation, and
supernatant removed. The cells were incubated on ice for 2 h
with 0.1 mg/mL monoclonal mouse anti-FIBCD1 antibody HG-
HYB-12-5 in PBS/0.5% BSA diluted 1:2 in 100µL cell suspension.
Monoclonal anti-ovalbumin antibody was used as an isotype
control. Then, the cells were washed three times and incubated
in darkness on ice for 1 h with FITC-conjugated goat anti-
mouse antibody diluted 1:10 in PBS/0.5% BSA and 1:2 in 100
µL cell suspension. Finally, the cells were washed three times,
diluted in 1.5mL PBS/0.5% BSA, and analyzed on a Benson
Dickinson FACS Calibur (BD Biosciences, Franklin Lakes, NJ,
United States) using CELL QuestTM (BD Biosciences, Franklin
Lakes, NJ, United States) and FlowJo 8.8.6 software (FlowJo, LLC,
Ashland, OR, United States).
Cell Culture Stimulation Conditions,
Relative Gene Expression, and Protein
Expression
For stimulations of transfected cells, A549 cells transfected with
sham and FIBCD1, respectively, were harvested by incubation
with 0.5% trypsin/EDTA in DPBS and centrifugation at 350 ×
g for 5min. Cells were suspended in media, counted using a
haemocytometer, and seeded at a density of 106 cells/well/2mL
media in 6-well culture plates or 250,000 cells/well/0.5mL media
in 24-well culture plates (80% confluence). After ∼8 h, the
adherent cells were washed with sterile DPBS, added 2 or 0.5mL
serum-free media, and incubated overnight. Then, cells were
stimulated by removing the media and adding 2mL of fresh
serum-free media containing 100 µL conidia, AIF, β-1,3-glucan,
chitin, galactomannan, or acBSA (ligand control) diluted in
sterile DPBS or 0.5mL of fresh serum-free media containing 22.2
µL human TLR agonist diluted in endotoxin-free water to each
well and incubating 0, 4, and 8 h. All stimulations were performed
as technical duplicates and biological triplicates.
At each time point, culture supernatant was removed from
the cells and used for detection of secreted IL-8 by use
of the human CXCL8/IL-8 DuoSet kit and keeping to the
recommendations of the manufacturer. For RNA analysis, the
cells were washed with DPBS, added TRIzol Reagent, and stored
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at −20◦C. Total RNA was isolated from cells stimulated 8 h
with 500µg/mL AIF, β-1,3-glucan, or chitin, and cells incubated
with DPBS for 8 h as a reference. TRIzol Reagent from technical
duplicates of stimulated cells was pooled together, while five
biological replicates from DPBS-incubated cells were pooled
together to three independent samples. Total RNA was isolated
from TRIzol Reagent according to the recommendations of the
manufacturer in a fume cupboard treated with RNase ZAP R©.
cDNA synthesis by M-MLV reverse transcriptase and oligo-dT
primers was subsequently performed in keep with manufacturer’s
instructions. The RNA concentration and purity (260/280)
was determined by NanoDrop R© ND-1000 spectrophotometry
(Thermo Fisher Scientific Inc., Waltham, MA, United states).
Then, quantitative PCR (qPCR) was performed targeting 21
different genes involved in immunological response and barrier
function (CCL2, CCL5, CCL20, CXCL2, CSF2RA, TNF, TSLP,
IL1B, IL6 IL8, IL10, IL12B, IL13, IL25, IL33, MUC1, MUC13,
MUC5AC, TJP1, OCLN, ICAM1) and two housekeeping genes
(GAPDH, TBP) for normalization. Custom TaqMan R© Array 96-
well Plates containing dried assay of these genes were added 10
µL cDNA diluted 1:2 in 2 X TaqMan R© fast advanced master
mix as single copies and qPCR was performed according to the
recommendations of the manufacturer using a StepOnePlusTM
Real-Time PCR System (Applied Biosystems R©, Thermo Fisher
Scientific Inc., Waltham, MA, USA) and StepOneTM v2.1
software (Applied Biosystems R©, Thermo Fisher Scientific Inc.,
Waltham, MA, USA). A no-template control was included
to exclude DNA contamination. Relative expression of the
genes was calculated by qBase plus software (Biogazelle, Gent,
Belgium), which uses threshold cycle values of target genes
and reference genes to determine calibrated normalized relative
quantities (CNRQs). For protein analysis, cells were washed twice
with DPBS, added 11 µL/cm2 RIPA buffer/protease inhibitors
(1 tablet per 50mL)/phosphatase inhibitors (1 tablet per 10mL),
and incubated on a shaker at 4◦C for 60min. Cellular debris
were sedimented by centrifugation at 4◦C, 10,000 rpm (Sigma
1–16 k refrigerated centrifuge, Sigma-Aldrich Co., St Louis,
MO, United States) for 5min and supernatants were stored at
−20◦C. Protein concentrations were determined by Bradford in
accordance with the recommendations of the manufacturer and
samples were prepared for SDS-PAGE by boiling three parts cell
lysate with one part SDS-PAGE sample buffer on a 99◦C heating
block for 1min. The samples were alkylated by adding one tenth
1.4M IAA, separated on a 4–12% polyacrylamide gradient gel (19
µg protein per well) usingMOPS running buffer, and analyzed by
Western blotting as described in the following section.
Western Blotting
Proteins separated by SDS-PAGE were transferred onto a
polyvinylidene difluoride membrane by semidry electroblotting
(1.2 mA/cm2 for 1 h or 0.2 mA/cm2 overnight) using transfer
buffer (75mM Tris-base/39mM glycine/0.037% (w/v) SDS/20%
ethanol) and blocked with TBS/0.5MNaCl/0.1% Tween/5% non-
fat dry milk at 4◦C for several hours. FIBCD1 was detected by
probing the blot with 2µg/mL mouse monoclonal anti-FIBCD1
antibody HG-HYB-12-2 or mouse monoclonal anti-FIBCD1-
FReD antibody HYB-11-14-25 diluted in TBS/0.5M NaCl/0.1 %
Tween/2.5% non-fat dry milk at 4◦C overnight. Mucins were
detected by probing the blot with 0.22µg/mL rabbit monoclonal
anti-MUC-1 antibody, 2µg/mL rabbit polyclonal anti-MUC-
13 antibody, or 6.6µg/mL mouse monoclonal anti-MUC-5AC
antibody in 20mL TBS/0.5M NaCl/0.1% Tween/2.5% non-fat
dry milk at 4◦C overnight. Mouse monoclonal anti-GAPDH
antibody (0.01µg/mL) was used as control. Excess antibody was
removed by extensive washing with TBS/0.5MNaCl/0.1% Tween
and the blot was incubated 1 h with either HRP-conjugated rabbit
anti-mouse antibody diluted 1:10,000 or HRP-conjugated goat
anti-rabbit antibody diluted 1:20,000 in TBS/0.5M NaCl/0.1%
Tween. The blot was washed, developed using ECL standard
method, detected by Fusion Fx7 (Vilber Lourmat, Collégien,
France), and depicted using FUSION-CAPT version 15.18
software (Vilber Lourmat, Collégien, France). Precision Plus
ProteinTM KaleidoscopeTM Standards were used as size markers.
Between incubations with anti-mucin and -GAPDH antibodies,
the membrane was stripped and blocked. Stripping was achieved
by washing once with TBS/0.5M NaCl/0.1% Tween, boiling in
deionized water for 10min, and washing twice with TBS/0.5M
NaCl/0.1% Tween.
Expression of Results and Statistics
Unless otherwise stated, data are expressed as mean ± SEM and
differences were considered to be statistically significant when
p < 0.05. Log2-transformed IL-8 secretion data was analyzed by
one- or two-way ANOVA with Tukey’s post-hoc tests depending
on the number of independent variables using Prism software
(version 6.0d, Graphpad, San Diego, CA, USA). Multilevel
mixed-effects linear regression models were used to determine
whether changed RNA expression of various genes was associated
with stimulant, genotype, or a combined effect of these variables
using the XTMIXED function of STATA13 (STATA Corp,
College Station, TX, USA). Genes were analyzed separately using
multilevel mixed-effects linear regression models to compensate
for random effects. Log2 (CNRQ) was outcome, while stimulant,
genotype, and interaction between these were fixed effects, and
biological triplicate and culture plate variation were random
effects (Table S1). Final models were evaluated for normality
by prediction of residuals and assessment of their normal
distribution by graphic (qq-plot, histogram, and box plot) and
numeric methods (Skewness/Kurtosis and Shapiro-Wilk tests).
P-values were extracted from the models using the LINCOM
function.
RESULTS
FIBCD1 Is Expressed on the Apical Surface
of Human Bronchial and Alveolar Epithelial
Cells
We have previously shown that FIBCD1 is expressed apically by
epithelial cells of mucous membranes, i.e. the small and large
intestine and salivary glands (14), and therefore hypothesized
that it is also expressed in the lung mucosal membrane. First,
we determined FIBCD1 mRNA expression in a series of human
tissues (Figure 1A). The highest expressional levels were found
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in the respiratory tract (lung and trachea), gastrointestinal tract
(colon and small intestine), testis, placenta, and brain. Then, we
performed an immunohistochemical (IHC) analysis of human,
non-cancerous lung tissue (control) from patients with lung
cancer (Figures 1B–E) and from patients with pulmonary A.
fumigatus infection (Figures 1F–I). FIBCD1 immunostaining
was detected in submucosal glands, alveoli, and bronchioles with
more intense staining coincident with areas of inflammation
(Figures 1G,H). Bronchiolar FIBCD1 was restricted to the
apical surface of ciliated epithelial cells (Figures 1E,I) similar
to the expression observed in the gastrointestinal tract (14).
Similar results were observed by von Huth et al. (25) in non-
malignant, non-inflammatory, and histologically normal, human
tissues. Thus, FIBCD1 is expressed apically in the lung mucosal
membrane and seemingly increased in areas of inflammation.
FIBCD1 Binds to A. fumigatus Dependent
on Cell Wall PAMP Availability
We next examined if FIBCD1 is capable of recognizing A.
fumigatus hyphae. Fluorescence microscopy revealed FIBCD1
recognition of fully-grown hyphae (Figures 2A,B), including
chitin-rich septum regions (Figures 2C,D) and mycelial frame
of budding hyphae (Figures 2E,F). We further examined co-
localization between the chitin-binding fluorescent-labeledWGA
and FIBCD1 in different morphological stages. Co-localization
was observed in all stages characterized by exposed cell wall
polysaccharides including swollen conidia, germ tubes, budding
regions, and growing hyphae (Figure 2G), while no binding of
FIBCD1 observed on resting conidia (Figure S1). Thus, FIBCD1
binds to A. fumigatus dependent on cell wall PAMP availability.
FIBCD1 Recognizes a Composite Structure
in AIF Not Exclusively Through the S1
Binding Site
To evaluate if FIBCD1 binds fungal chitin, we isolated the
chitin-containing structural skeleton of the A. fumigatus cell
wall (AIF) and performed a pull-down assay (Figure 3A).
We show that rFIBCD1-FReD binds AIF and pull-down
using Dectin-1 fc, rMBL, and WGA demonstrated that cell
wall components β-1,3-glucan, galactomannan, and chitin,
respectively, were preserved after treatment (12, 26). We
observed bands corresponding to FIBCD1-FReD monomeric,
dimeric, trimeric, and tetrameric structures, at ∼25, 50, 75,
and 100 kDa, respectively, and large Dectin-1 fc structures of
∼120 and 300 kDa. We observed bands corresponding to higher
polymeric structures of rMBL, which assembles into trimers
and hexamers of trimers. The smallest rMBL band is ∼30
kDa, which is comparable to the rMBL monomer. Finally, we
observed a band corresponding to the WGA monomer at ∼18
kDa.
FIBCD1 exhibits calcium-dependent binding of chitin
and other acetylated compounds through a conserved S1
hydrophobic pocket of the FReD (14, 15). Therefore, we
hypothesized that FIBCD1 binds A. fumigatus AIF through a
similar mechanism. To investigate this, we performed a pull-
down assay using AIF in the presence or absence of calcium and
FIGURE 1 | FIBCD1 RNA is expressed in various human tissues and FIBCD1
protein is expressed on the apical site of lung epithelium and within
submucosal glands. (A) Relative expression of FIBCD1 mRNA in various
human tissues relative to expression in thymus. Technical triplicates. (B–E) IHC
staining of FIBCD1 in non-cancerous lung tissue from a 68-year-old female
patient with adenocarcinoma (scale bars: 100µm, magnification: 40X).
FIBCD1 was detected in submucosal glands (B), non-inflamed alveoli (C),
inflamed alveoli (D), and inflamed bronchioles (E). (G–I) IHC staining of FIBCD1
in lung tissue from a 63-year-old male patient with A. fumigatus infiltration
(scale bars: 100µm, magnification: 40X). Formation of aspergilloma was
observed (F, scale bar: 200µm, magnification: 20X) and FIBCD1 was detected
in alveoli with atelectasis (G) and pneumonia (H) and in bronchioles (I).
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FIGURE 2 | FIBCD1 recognizes chitin-rich regions of A. fumigatus during different life stages. Bright field (A,C,E) and fluorescence (B,D,F,G) microscopy of A.
fumigatus. (A,B) A total of 107 A. fumigatus conidia/mL was grown in SD medium to form fungal hyphae followed by staining with Alexa 488-labeled FIBCD1 as
described in materials and methods. A clear recognition of fungal hyphae by FIBCD1 was observed. Image: 10X objective. (C–F) 5·106 A. fumigatus conidia/mL were
grown in SD broth medium and stained with Alexa 488-labeled FIBCD1. rhFIBCD1 recognized the chitin-rich A. fumigatus septum of fully-grown hyphae. Image 40X
and 20X objectives. (G) 104 A. fumigatus conidia/mL was grown in SD medium for various time points (6, 8, and 12 h) at 37◦C and stained with Alexa 633-labeled
WGA and Alexa 488-labeled FIBCD1. FIBCD1 failed to bind resting conidia (Figure S1). We observed co-localization of regions recognized by Alexa 488-labeled
FIBCD1 and Alexa 633-labeled WGA.
acetate (Figure 3B). The insoluble, separate cell wall components
β-1,3-glucan and chitin (beads) were used as negative and
positive control, respectively (14). Surprisingly, our results show
that FIBCD1 binding of AIF is calcium-independent and less
sensitive to acetate than purified chitin, suggesting that FIBCD1
binds AIF through additional binding sites outside the S1 binding
pocket, potentially involving other polysaccharide structures
found in AIF. Therefore, we performed a pull-down assay of
wild type FIBCD1-FReD and FIBCD1-FReD with a site-directed
mutagenesis abolishing the binding properties of the S1 binding
site, A432V (15), using AIF and chitin beads (positive control)
(Figure 3C). Our results show that FIBCD1-FReD is capable of
binding AIF when the binding activity of the S1 binding site is
disrupted.
FIBCD1 Overexpression Suppresses IL-8
Secretion After Stimulation With
A. fumigatus AIF and Galactomannan
A549 lung epithelial cells secrete IL-8 after exposure to A.
fumigatus irradiated conidia and mycelium (27), and we
confirmed a time- and dose-dependent induction of IL-8
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FIGURE 3 | rFIBCD1-FReD binds A. fumigatus AIF calcium- and acetate-independently. (A) The presence and binding activity of β-1,3-glucan, galactomannan, and
chitin in AIF was validated by pull down of know ligands Dectin-1 fc, rMBL, and WGA. The samples were subjected to SDS-PAGE and analyzed by silver staining.
Color is adjusted to gray scale. (B)Western blot showing FIBCD1-FReD pull down by AIF-associated polysaccharides in the presence of calcium (5mM CaCl2), EDTA
(10mM), and acetate (100mM). 2mg of AIF, β-1,3-glucan, and chitin beads were incubated with 5µg/mL FIBCD1-FReD and pull down was performed as described.
Data represent three independent experiments. (C) Western blot showing wild type and A432V mutant FIBCD1-FReD pull down by chitin beads and AIF. Color is
adjusted to gray scale. Lane 1, 3: chitin beads, Lane 2: AIF.
following stimulation with live conidia and AIF (Figure S2).
Since A549 cells constitutively expressed low or non-detectable
levels of FIBCD1 protein (Figure 4B, top panel), we increased
FIBCD1 expression by transfecting A549 cells with the full-length
human fibcd1 gene and compared these to sham-transfected
A549 cells. In A549 FIBCD1-transfected cells, FIBCD1 protein
expression was confirmed by Western blot analysis (Figure 4A)
and surface expression by flow cytometry (Figure 4B, bottom
panel). Stimulation of the transfected A549 cells with AIF, β-
1,3-glucan, chitin, or galactomannan (Figures 4C–L) resulted
in time- and dose-dependent IL-8 secretion. FIBCD1 over-
expression mediated basal suppression of IL-8 secretion in
cells without stimulus (DPBS alone). This FIBCD1-mediated
IL-8 suppression was abolished during stimulation with β-1,3-
glucan (Figures 4E,F) and chitin (Figures 4G,H). Chitin induced
a very low IL-8 response, while β-1,3-glucan induced a high
IL-8 response in both cell types. However, FIBCD1-mediated
suppression of IL-8 secretion was increased by stimulation with
AIF (Figures 4C,D) and galactomannan (Figures 4I,J). A similar
response was observed against the positive control ligand acBSA
(Figures 4K,L). Hence, FIBCD1 overexpression suppresses IL-8
secretion and maintains this suppression after stimulation with
A. fumigatus AIF and galactomannan.
FIBCD1 Suppresses Mucin and
Inflammatory Gene Expression and
Increases Expression of Genes Involved in
Mucosal Barrier Function
Next, we investigated the effect of FIBCD1 transfection on lung
epithelial and immune response gene expression after incubation
with AIF, β-1,3-glucan, and chitin (Figure 5 and Table S1).
Transfected FIBCD1 expression suppressed the RNA expression
of proinflammatory cytokines, chemokines, and mucins (CCL20,
CSF2RA, TNF, IL1B, IL8, MUC1, MUC13, and MUC5AC) and
increased RNA expression of barrier function proteins (OCLN
and ICAM1). FIBCD1-mediated suppression of CCL20, IL1B,
IL8, and ICAM1 was reversed in the presence of β-1,3-glucan
or chitin. In contrast, stimulation with AIF generally increased
FIBCD1-mediated suppression of CCL2, CSF2RA, IL1B, IL8,
MUC13, and MUC5AC and FIBCD1-mediated induction of the
Th2-associated cytokine IL12B. CXCL2, IL6, IL10, IL25, and IL33
were not detected (data not shown). We further evaluated the
protein expression of genes with threshold cycle values below 25
(data not shown) regulated at least 2-fold by FIBCD1 expression
and not already examined (MUC-1, MUC-13, and MUC-5AC)
(Figure 6). In keep with the qPCR data, we observed FIBCD1-
mediated suppression of MUC-1,−13, and−5AC in the presence
or absence of AIF. Increased FIBCD1-mediated suppression
in the presence of AIF was only observed on MUC-13 and
−5AC. Thus, FIBCD1 overexpression suppresses mucins and
inflammatory gene expression and increases expression of genes
involved in mucosal barrier function.
FIBCD1 Influences IL-8 Secretion From
A549 Lung Epithelial Cells in Response to
TLR2, TLR4, and TLR5 Agonists
Finally, we examined whether FIBCD1 expression modulated
TLR-induced IL-8 secretion by stimulating A549 sham- and
FIBCD1-transfected cells with 10 different TLR agonists and
measuring IL-8 levels in culture supernatants (Figure 7).
We found that FIBCD1 in particular suppressed TLR2 and
−4 agonist-induced IL-8 secretion and that TLR5 agonist
Frontiers in Immunology | www.frontiersin.org 8 September 2018 | Volume 9 | Article 1967
Jepsen et al. FIBCD1 Regulates Anti-A. fumigatus Response
FIGURE 4 | Overexpression of FIBCD1 on the surface of A549 cells inhibits
secretion of IL-8. The phenotype of sham- and FIBCD1-transfected A549 cells
(Continued)
FIGURE 4 | was analyzed by Western blotting (A) and flow cytometry (B).
(A) Western blot of cell lysate from sham- and FIBCD1-transfected A549 cells
under reducing and non-reducing conditions revealed the presence of four
known oligomeric forms of FIBCD1 in the FIBCD1-transfected cells when
probed with the anti-FIBCD1 mAb clone HG-HYB 12-2. (B) Flow cytometry of
sham- and FIBCD1-transfected A549 cells showed surface expression of
FIBCD1 on FIBCD1-transfected cells and none on sham-transfected cells
when using anti-FIBCD1 antibody HG-HYB 12-5 for detection. (C–L) A549
sham- and FIBCD1-transfected cells were seeded at a density of one million
cells in 2mL of media per well of a 6-well tissue culture plate and
serum-starved overnight prior to stimulation with two different concentrations
of several components associated with A. fumigatus or FIBCD1 for 0, 4, and
8 h and the concentration of secreted IL-8 was determined by sandwich ELISA
as described. Left column: Time-dependent IL-8 secretion to 1,000 µg AIF
(C), 1,000 µg β-1,3-glucan (E), 1,000 µg chitin (G), 1,000 µg galactomannan
(I), or 500µg acBSA (K) per 2mL medium. Right column: Dose-dependent
IL-8 secretion after 8 h of stimulation with AIF (D), β-1,3-glucan (F), chitin (H),
galactomannan (J), or acBSA (L). Data are presented as mean ± SEM from
three independent experiments. Duplicate cell cultures were used for each of
the three independent experiments and ELISA measurements were performed
in duplicates on each of these. Data were analyzed by two-way ANOVA,
following Tukey’s test, #p < 0.05, ##p < 0.01, ###p < 0.001, and
#### p < 0.0001 relative to 0 h or DPBS-treated cells. *p < 0.05 and
**p < 0.01, relative to A549 sham cells stimulated with the same stimulant for
the same time period.
circumvented IL-8 suppression. These findings are supported
by qPCR (Figure S4). Though TLR6/2,−7,−8, and −9 agonist-
induced IL-8 secretion was suppressed by FIBCD1 expression,
it differed little from the basal suppression. Contrary to this,
TLR2,−4, and−5 agonist-induced IL-8 secretion was changed at
least 2-fold from basal suppression. Similar results were observed
after 4 h of stimulation (Figure S3). Hence, FIBCD1 expression
influences TLR2,−4, and−5 agonist-induced IL-8 secretion.
DISCUSSION
We previously reported FIBCD1 protein expression at the
brush border of human intestinal epithelium and identified
binding of crab shell chitin in the S1 binding site of FIBCD1-
FReD (14, 15). In the current study, we observed FIBCD1
protein expression at the apical site of human bronchial and
alveolar epithelium and binding between FIBCD1 and A.
fumigatus dependent on cell wall availability, as well as an
S1 site-independent AIF recognition. We observed FIBCD1-
mediated suppression of IL-8 secretion, mucin production,
and transcription of genes involved in inflammatory signaling
and FIBCD1-mediated induction of tight junction and cell
adhesion molecule transcription. Additionally, we show that this
regulation was modulated by stimulation with A. fumigatus cell
wall and individual cell wall components, i.e., β-1,3-glucan and
chitin, and FIBCD1 expression effected TLR agonist-induced
IL-8 secretion.
Fluorescence microscopy of different A. fumigatus
morphotypes (Figure 2) showed that soluble FIBCD1 binding
was dependent on conidial germination and concomitant
exposure of cell wall polysaccharides. Thus, FIBCD1’s role in the
immune response against A. fumigatus may be associated
with the expanded immune response, i.e. opsonization
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FIGURE 5 | Overexpression of FIBCD1 affects RNA expression of genes associated with immunological responses at mucosal sites. Relative RNA expression of
cytokines (A-J), mucins (K-M), TJ proteins (N-O), and adhesion protein (P) by A549 sham and A549 FIBCD1 cells in response to stimulation. One million A549 lung
epithelial cells transfected with sham and hFIBCD1, respectively, were incubated with DPBS, 500µg/mL AIF, β-1,3-glucan, and chitin in 2mL serum-free complete
medium for 8 h. The culture supernatants were removed, 1mL TRIzol added to each well, RNA isolated, cDNA synthetized and tested, and qPCR performed. Data are
presented as mean ± SEM from three independent experiments. P-values are extracted from the multilevel linear regression models. #p < 0.05, ##p < 0.01, and
###p < 0.001 relative to DPBS-treated cells. *p < 0.05, **p < 0.01, and ***p < 0.001 relative to A549 sham cells stimulated with the same stimulant.
and chemotactic attraction of neutrophils to the site of
inflammation (1). Furthermore, we observed co-localization
between chitin-rich zones and areas recognized by FIBCD1,
which led us to investigate interaction between FIBCD1 and
the chitin-containing structural skeleton of the A. fumigatus
cell wall (AIF). Pull-down experiments (Figure 3) revealed that
FIBCD1 recognizes AIF independently of calcium and the S1
binding site with less sensitivity to acetate compared to that of
chitin.
Chitin is the only component of the cell wall known as a
FIBCD1 ligand, which it binds through the S1 binding site (14).
These findings support that FIBCD1 recognizes fungal chitin
through the S1 binding site, but also recognizes other cell wall
structures found in AIF, possibly through conjunctional binding
sites or separately in other unknown binding sites.
Similar to a previous study using A549 lung epithelial cells
(27), we observed a time- and dose-dependent secretion of
IL-8, a proinflammatory chemokine that attracts neutrophils
and thereby plays an important role in the inflammatory
response against A. fumigatus hyphae (1). Stimulation of
A549 lung epithelial cells overexpressing FIBCD1 (Figure 4)
revealed a suppression of IL-8 secretion, which is abolished
by stimulation with β-1,3-glucan and chitin and increased by
AIF, galactomannan, and acBSA. As a non-FIBCD1 binding
ligand, we expect the observed effect of β-1,3-glucan on
FIBCD1-mediated suppression of IL-8 secretion to be caused
by the activation of pathways that either deactivate FIBCD1,
decrease its expression, or induce IL-8 production through
circumventing pathways, possibly through the well-known β-
1,3-glucan PRR Dectin-1 (12). Different effects of the FIBCD1
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FIGURE 6 | Overexpression of FIBCD1 modulates mucin protein production. A549 sham- and FIBCD1-transfected cells were seeded at a density of one million cells
in 2mL of media per well of a 6-well tissue culture plate and serum-starved over night prior to incubation with DPBS or 500µg/mL AIF in 2mL serum-free media for 0,
4, 8, and 24 h. (A)Western blot analysis was performed as described using 19 µg of cell lysate per well. Lane 1, 3, 5, 7, 9, 11, 13: A549 sham-transfected cells, Lane
2, 4, 6, 8, 10, 12, 14: A549 FIBCD1-transfected cells. The Western blot shown is from one of three independent experiments yielding similar results. Color is adjusted
to gray scale. (B–D) Western blots were quantified using ImageJ software. The values obtained after 8 h are expressed as mean ± SEM of the ratio of MUC-1 (B),
MUC-13 (C), and MUC-5AC (D) to GAPDH from three independent experiments. Data were analyzed by two-way ANOVA, following Tukey’s test, #p < 0.05, ##p <
0.01, and ###p < 0.001 relative to control cells. *p < 0.05, **p < 0.01, and ***p < 0.001 relative to A549 sham cells stimulated with the same stimulant.
ligands AIF, chitin, and acBSA were observed, which is likely
caused by particle size and source differences known to impact
epithelial responses against chitin (28, 29). Previous studies
have shown that large particles fail to induce an inflammatory
response, while intermediate and small particles protect against
Th2-associated allergy (28, 29). In the current study, the
exact size of the chitin particles is unknown, however, large,
insoluble fragments were observed by bright field microscopy
during the stimulation study, which may have effected the
interaction between FIBCD1 and chitin. Contrary to this, AIF
was administered in intermediate particle size (<40 µm) and
acBSA and galactomannan are both soluble molecules. It is
currently unclear if the FIBCD1-mediated suppression of IL-8
secretion in response to galactomannan is caused bymere particle
size, intersections of signaling pathways or by direct or indirect
interaction between FIBCD1 and galactomannan. It is, however,
clear that galactomannan does not bind to the S1 binding site of
FIBCD1-FReD (Figure S5).
We observed a FIBCD1-mediated transcriptional suppression
of proinflammatory cytokines, chemokines, and mucins and
an induction of barrier function gene expression (Figure 5).
During the anti-fungal response, several proteins of the genes
suppressed by FIBCD1 are released from epithelium to aid in
the response. They cause increased inflammation, recruitment
of neutrophils, monocytes, and mast cells to the site of
inflammation, stimulation of naïve Th cell polarization to
Th2 cells, and facilitate homing of these cells. Finally, they
induce secretion of MUC-5AC and epithelial expression of
MUC-1 and −13, and disrupt epithelial apical junctional
complexes, which further enhances inflammation and antigen
presentation by dendritic cells (30–40). Thus, FIBCD1 may
serve as a general suppressor of airway inflammation. Similar
to the IL-8 secretion observations, stimulation with β-1,3-
glucan and chitin diminish and AIF increases FIBCD1-mediated
suppression.
Mucociliary clearance is the primary defense mechanism
against A. fumigatus in the bronchioles (6) and is highly
dependent on the synthesis, glycosylation, and release of secreted
and membrane-bound mucins (37, 41). FIBCD1-mediated
suppression of MUC-1 and MUC-5AC and an AIF-increased
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FIGURE 7 | Overexpression of FIBCD1 on the surface of A549 cells inhibits
TLR agonist effects. A549 sham- and FIBCD1-transfected cells were seeded
at a density of 250,000 cells in 0.5mL of media per well of a 24-well tissue
culture plate and serum-starved overnight prior to stimulation. The cells were
stimulated with TLR1/2 (A), 5 (F), and 6/2 (G) agonists (0.67µg/mL), TLR2 (B)
agonist (6.7·107 cells/mL), TLR3a (C) and 3b (D) agonists (8.9µg/mL), TLR4
(E) agonist (4.4µg/mL), TLR7 (H) and 8 (I) agonists (1.8µg/mL), and TLR9 (J)
agonist (0.068µg/mL) for 8 h and the concentration of secreted IL-8 was
determined by sandwich ELISA as described in methods. Data are presented
as mean ± SEM from three independent experiments. Duplicate cell cultures
were used for each of the three independent experiments and ELISA
measurements were performed in duplicates on each of these. Data were
analyzed by two-way ANOVA, followed by Tukey’s post-test, #p < 0.05,
##p < 0.01, ###p < 0.001, and ####p < 0.0001 relative to
DPBS-treated cells. *p < 0.05, **p < 0.01, and ***p < 0.001 relative to A549
sham cells stimulated with the same stimulant.
FIBCD1-mediated suppression of MUC-13 and MUC-5AC
were observed by Western blotting of cell lysates from A549
lung epithelial cells (Figure 6). This indicates that FIBCD1
expression impacts mucus composition and thereby fungal
clearance. However, whether these alterations are beneficial
for fungi or host is unclear. Additionally, MUC-5AC is a
secretory mucin (41) and the lack of vesicle storage in the
A549 FIBCD1-transfected cells compared to the A549 sham-
transfected cells may reflect increased release as well as decreased
production.
Finally, we observed that FIBCD1 overexpression affects
the inflammatory response mediated by TLRs in A549 lung
epithelial cells (Figure 7). The overexpression decreases
TLR2- and TLR4-induced IL-8 secretion and increases
TLR5-induced IL-8 secretion. Intriguingly, these TLRs are
associated with different outcomes of fungal infections. Several
studies have investigated the role of TLR2 and TLR4 in the
immunological response against A. fumigatus and found
that their expression is required for optimal host defense
(6, 42, 43). The investigation of TLR5’s involvement in anti-A.
fumigatus responses is fairly limited, and it has early been
demonstrated that TLR5 have no influence on the anti-A.
fumigatus response (42). However, Rodland et al. (44) observed
an increased RNA expression of the receptor in human
monocytes challenges with A. fumigatus and later found that
TLR5 has an enhancing effect on the viability of conidia
(45).
Collectively, our findings demonstrate FIBCD1 as human
lung epithelial PRR that recognizes the cell wall of A. fumigatus
and suppresses epithelial inflammatory signaling and mucin
production. FIBCD1 activation may have a beneficial effect
by decreasing inflammatory damage or an adverse effect
by diminishing anti-fungal responses such as recruitment of
neutrophils and mucin production.
AUTHOR CONTRIBUTIONS
The experiments were designed by CJ, LD, AS, GS, ST, and UH.
CJ, LD, KC, JM, MH, and ON performed the experiments. CJ
performed statistical analysis of the data. The reagents, materials,
and analysis tools were provided by ON, AS, GS, and UH. CJ, ST,
and UH wrote the paper.
FUNDING
This work was supported by The Danish Medical Research
Council, The Independent Research Fund Denmark, The Novo
Nordisk Foundation, The Lundbeck Foundation, Fonden til
Lægevidenskabens Fremme, The Beckett foundation, and The
Gangsted Foundation.
ACKNOWLEDGMENTS
We thank René Holst for help with the multilevel linear
regression models, Theresa Thomsen for providing the FIBCD1
deletion mutants, and Jan Mollenhauer for providing the pDEST
vector.
Frontiers in Immunology | www.frontiersin.org 12 September 2018 | Volume 9 | Article 1967
Jepsen et al. FIBCD1 Regulates Anti-A. fumigatus Response
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2018.01967/full#supplementary-material
Figure S1 | FIBCD1 does not recognizes A. fumigatus resting conidia. Bright field
(A) and fluorescence (B) microscopy of A. fumigatus. (A,B) A. fumigatus
conidia/mL was grown in SD medium to form fungal hyphae followed by staining
with Alexa 488-labeled FIBCD1 as described in materials and methods. A clear
recognition of fungal hyphae by FIBCD1 was observed while no staining was seen
of the resting conidia indicated by arrows was seen. Image: 20X objective.
Figure S2 | A. fumigatus conidia and AIF induce IL-8 secretion by A549 wild type
cells time- and dose-dependently. Wild type A549 cells were seeded at a density
of 3·105 cells in 2mL of media per well of a 12-well tissue culture plate and
serum-starved over night prior to stimulation and the concentration of secreted
IL-8 was determined by sandwich ELISA as described in methods. Left panels:
Time-dependent IL-8 secretion to 3·105 conidia (A) and 800µg AIF (C) per 2mL
medium. Right panels: Dose-dependent IL-8 secretion after 8 h of stimulation with
conidia (B) and AIF (D). Data are presented as mean ± SEM from three
independent experiments. ELISA measurements were performed in triplicates
(A,C) and duplicates (B,D) for each of the three independent experiments. Data
were analyzed by two-way (A,C) and one-way (B,D) ANOVA, followed by Tukey’s
post-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 relative to
previous time or dosage.
Figure S3 | Overexpression of FIBCD1 on the surface of A549 cells influences
TLR agonist effects after 4 h. A549 sham- and FIBCD1-transfected cells were
seeded at a density of 250,000 cells in 0.5mL of media per well of a 24-well
tissue culture plate and serum-starved overnight prior to stimulation. The cells
were stimulated with TLR1/2 (A), 5 (F), and 6/2 (G) agonists (0.67µg/mL),
TLR2 (B) agonist (6.7·107 cells/mL), TLR3a (C) and 3b (D) agonists
(8.9µg/mL), TLR4 (E) agonist (4.4µg/mL), TLR7 (H) and 8 (I) agonists
(1.8µg/mL), and TLR9 (J) agonist (0.068µg/mL) for 4 h and the concentration
of secreted IL-8 was determined by sandwich ELISA as described in methods.
Data are presented as mean ± SEM from three independent experiments.
Duplicate cell cultures were used for each of the three independent
experiments and ELISA measurements were performed in duplicates on each
of these. Data were analyzed by two-way ANOVA, following Tukey’s test,
#p < 0.05, ##p < 0.01, ###p < 0.001, and ####p < 0.001 relative to
DPBS-treated cells. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 relative to
A549 sham cells stimulated with the same stimulant.
Figure S4 | Overexpression of FIBCD1 on the surface of A549 cells influences
TLR agonist effects. A549 sham- and FIBCD1-transfected cells were seeded
at a density of 250,000 cells in 0.5mL of media per well of a 24-well tissue
culture plate and serum-starved overnight prior to stimulation. The cells were
stimulated with TLR1/2 and 5 agonists (0.67µg/mL), TLR2 agonist (6.7·107
cells/mL), and TLR4 agonist (4.4µg/mL) for 4 h (A) and 8 h (B). The culture
supernatants were removed, 0.5mL TRIzol added to each well, RNA isolated,
cDNA synthetized, and qPCR performed. Data are presented as mean ± SEM
from three independent experiments and qPCR measurements were performed
in duplicates on each of these. Data were analyzed by two-way ANOVA,
following Tukey’s test, #p < 0.05, ##p < 0.01 and ###p < 0.001, relative
to DPBS-treated cells. ∗∗p < 0.01, and relative to A549 sham cells stimulated
with the same stimulant.
Figure S5 | Competitive ELISA showing galactomannan’s effect on binding
between acBSA and FIBCD1-FReD. A maxisorp immuno plate was coated
with 1µg/mL acBSA in ELISA coating buffer overnight. PBS, acetate,
mannan, and galactomannan were loaded in a 2-fold dilution series in
TBS/0.05% tween/5mM CaCl2 starting at 100mM, 2 mg/mL, and 2
mg/mL, respectively, along with 0.5µg/mL FIBCD1-FReD. PBS was used as
a control for decreased Ca2+ presence by the addition of polysaccharides
suspended in PBS, calcium content started at 2.5mM CaCl2. FIBCD1-FReD
was detected by 1µg/mL HG-HYB-12-6 in TBS/0.05% tween/5mM CaCl2
and HRP-conjugated rabbit anti-mouse antibody. Data represent three
independent experiments and is shown as mean ± SEM. ELISA
measurements were performed in duplicates for each of the three
independent experiments.
Table S1 | Multilevel linear regression models. Results of the multilevel linear
regression models used to analyze relative mRNA expression of cytokines,
mucins, adhesion proteins, and TJ proteins in A549 sham and A549 FIBCD1
cells in response to stimulation (Figure 6).
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